Why GoPro, Microsoft, Twitter and Two Other Stocks Are in Spotlight Today

Twitter Inc (NYSE:TWTR) was down about by 2.75% in the early afternoon, following reports about a possible change in the social network’s timeline some time this week. The new timeline would be of al algorithmic nature, reports suggested. This means that, instead of getting tweets in a reverse chronological order, users would get the ones that Twitter believes he/she is more interested in, first. Although this could prove interesting, people were worried that the change would lead less popular accounts into oblivion, and expressed their disconformity using the #RIPTwitter hashtag.

It seems like some hedge funds saw the tough times coming, and decided to leave Twitter Inc (NYSE:TWTR) before it was too late. During the third quarter of 2015, Daniel Benton’s Andor Capital Management, one the largest hedge fund investor of record sold all of its 1.5 million shares of the social media giant, same as Cliff Asness’ AQR Capital Management, which disposed of 814,578 shares over the period, closing out its stake in the firm.

Back to gainers, we’ve got Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) both slightly up on Monday afternoon following a Barron’s article that assured that both these stocks can offer a 30% upside.

“Concentrated drug portfolios may be a concern, but low valuations and strong free cash flow give them appeal,” author Jack Hough explained. The recent plummet in biotech stocks has opened an attractive entry point at some companies “that are already highly profitable and were inexpensive before the selling began.” Celgene and Gilead could be included in this group, and could be trading 30% higher over the next 12 months, he added.

Opposite to what happened with Twitter, AQR Capital Management seems quite bullish on both Celgene Corporation (NASDAQ:CELG) and Gilead Sciences, Inc. (NASDAQ:GILD). As of the end of the third quarter of 2015, the fund disclosed ownership of more than 4.76 million shares of Gilead, worth over $468 million, and 1.53 million shares of Celgene, valued at roughly $166 million.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.